Abstract
Summary
The generic sterile injectable are FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.
The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.
LPI (LP Information)' newest research report, the “Generic Sterile Injectable Industry Forecast” looks at past sales and reviews total world Generic Sterile Injectable sales in 2022, providing a comprehensive analysis by region and market sector of projected Generic Sterile Injectable sales for 2023 through 2029. With Generic Sterile Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Generic Sterile Injectable industry.
This Insight Report provides a comprehensive analysis of the global Generic Sterile Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Generic Sterile Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Generic Sterile Injectable market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Sterile Injectable and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Sterile Injectable.
The global Generic Sterile Injectable market size is projected to grow from US$ 50280 million in 2022 to US$ 75690 million in 2029; it is expected to grow at a CAGR of 75690 from 2023 to 2029.
United States market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Generic Sterile Injectable players cover 3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma and Dr. Reddy’s, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Sterile Injectable market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Monoclonal Antibodies
Cytokines
Insulin
Peptide Hormones
Vaccines
Others
Segmentation by application
Hospitals
Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
3M
Baxter Inc
Fresenius Kabi
Pfizer/Hospira
Novartis/Sandoz
Teva
Hikma
Sun Pharma
Dr. Reddy’s
Mylan
AstraZeneca Plc
Merck & Co., Inc
Hellberg Safety Ab
Key Questions Addressed in this Report
What is the 10-year outlook for the global Generic Sterile Injectable market?
What factors are driving Generic Sterile Injectable market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Generic Sterile Injectable market opportunities vary by end market size?
How does Generic Sterile Injectable break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.
LPI (LP Information)' newest research report, the “Generic Sterile Injectable Industry Forecast” looks at past sales and reviews total world Generic Sterile Injectable sales in 2022, providing a comprehensive analysis by region and market sector of projected Generic Sterile Injectable sales for 2023 through 2029. With Generic Sterile Injectable sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Generic Sterile Injectable industry.
This Insight Report provides a comprehensive analysis of the global Generic Sterile Injectable landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Generic Sterile Injectable portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Generic Sterile Injectable market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Generic Sterile Injectable and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Generic Sterile Injectable.
The global Generic Sterile Injectable market size is projected to grow from US$ 50280 million in 2022 to US$ 75690 million in 2029; it is expected to grow at a CAGR of 75690 from 2023 to 2029.
United States market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Generic Sterile Injectable is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Generic Sterile Injectable players cover 3M, Baxter Inc, Fresenius Kabi, Pfizer/Hospira, Novartis/Sandoz, Teva, Hikma, Sun Pharma and Dr. Reddy’s, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Generic Sterile Injectable market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Monoclonal Antibodies
Cytokines
Insulin
Peptide Hormones
Vaccines
Others
Segmentation by application
Hospitals
Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
3M
Baxter Inc
Fresenius Kabi
Pfizer/Hospira
Novartis/Sandoz
Teva
Hikma
Sun Pharma
Dr. Reddy’s
Mylan
AstraZeneca Plc
Merck & Co., Inc
Hellberg Safety Ab
Key Questions Addressed in this Report
What is the 10-year outlook for the global Generic Sterile Injectable market?
What factors are driving Generic Sterile Injectable market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Generic Sterile Injectable market opportunities vary by end market size?
How does Generic Sterile Injectable break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Generic Sterile Injectable Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Generic Sterile Injectable by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Generic Sterile Injectable by Country/Region, 2018, 2022 & 2029
2.2 Generic Sterile Injectable Segment by Type
2.2.1 Monoclonal Antibodies
2.2.2 Cytokines
2.2.3 Insulin
2.2.4 Peptide Hormones
2.2.5 Vaccines
2.2.6 Others
2.3 Generic Sterile Injectable Sales by Type
2.3.1 Global Generic Sterile Injectable Sales Market Share by Type (2018-2023)
2.3.2 Global Generic Sterile Injectable Revenue and Market Share by Type (2018-2023)
2.3.3 Global Generic Sterile Injectable Sale Price by Type (2018-2023)
2.4 Generic Sterile Injectable Segment by Application
2.4.1 Hospitals
2.4.2 Pharmacies
2.4.3 Online Pharmacies
2.5 Generic Sterile Injectable Sales by Application
2.5.1 Global Generic Sterile Injectable Sale Market Share by Application (2018-2023)
2.5.2 Global Generic Sterile Injectable Revenue and Market Share by Application (2018-2023)
2.5.3 Global Generic Sterile Injectable Sale Price by Application (2018-2023)
3 Global Generic Sterile Injectable by Company
3.1 Global Generic Sterile Injectable Breakdown Data by Company
3.1.1 Global Generic Sterile Injectable Annual Sales by Company (2018-2023)
3.1.2 Global Generic Sterile Injectable Sales Market Share by Company (2018-2023)
3.2 Global Generic Sterile Injectable Annual Revenue by Company (2018-2023)
3.2.1 Global Generic Sterile Injectable Revenue by Company (2018-2023)
3.2.2 Global Generic Sterile Injectable Revenue Market Share by Company (2018-2023)
3.3 Global Generic Sterile Injectable Sale Price by Company
3.4 Key Manufacturers Generic Sterile Injectable Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Generic Sterile Injectable Product Location Distribution
3.4.2 Players Generic Sterile Injectable Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Generic Sterile Injectable by Geographic Region
4.1 World Historic Generic Sterile Injectable Market Size by Geographic Region (2018-2023)
4.1.1 Global Generic Sterile Injectable Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Generic Sterile Injectable Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Generic Sterile Injectable Market Size by Country/Region (2018-2023)
4.2.1 Global Generic Sterile Injectable Annual Sales by Country/Region (2018-2023)
4.2.2 Global Generic Sterile Injectable Annual Revenue by Country/Region (2018-2023)
4.3 Americas Generic Sterile Injectable Sales Growth
4.4 APAC Generic Sterile Injectable Sales Growth
4.5 Europe Generic Sterile Injectable Sales Growth
4.6 Middle East & Africa Generic Sterile Injectable Sales Growth
5 Americas
5.1 Americas Generic Sterile Injectable Sales by Country
5.1.1 Americas Generic Sterile Injectable Sales by Country (2018-2023)
5.1.2 Americas Generic Sterile Injectable Revenue by Country (2018-2023)
5.2 Americas Generic Sterile Injectable Sales by Type
5.3 Americas Generic Sterile Injectable Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Generic Sterile Injectable Sales by Region
6.1.1 APAC Generic Sterile Injectable Sales by Region (2018-2023)
6.1.2 APAC Generic Sterile Injectable Revenue by Region (2018-2023)
6.2 APAC Generic Sterile Injectable Sales by Type
6.3 APAC Generic Sterile Injectable Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Generic Sterile Injectable by Country
7.1.1 Europe Generic Sterile Injectable Sales by Country (2018-2023)
7.1.2 Europe Generic Sterile Injectable Revenue by Country (2018-2023)
7.2 Europe Generic Sterile Injectable Sales by Type
7.3 Europe Generic Sterile Injectable Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Generic Sterile Injectable by Country
8.1.1 Middle East & Africa Generic Sterile Injectable Sales by Country (2018-2023)
8.1.2 Middle East & Africa Generic Sterile Injectable Revenue by Country (2018-2023)
8.2 Middle East & Africa Generic Sterile Injectable Sales by Type
8.3 Middle East & Africa Generic Sterile Injectable Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Generic Sterile Injectable
10.3 Manufacturing Process Analysis of Generic Sterile Injectable
10.4 Industry Chain Structure of Generic Sterile Injectable
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Generic Sterile Injectable Distributors
11.3 Generic Sterile Injectable Customer
12 World Forecast Review for Generic Sterile Injectable by Geographic Region
12.1 Global Generic Sterile Injectable Market Size Forecast by Region
12.1.1 Global Generic Sterile Injectable Forecast by Region (2024-2029)
12.1.2 Global Generic Sterile Injectable Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Generic Sterile Injectable Forecast by Type
12.7 Global Generic Sterile Injectable Forecast by Application
13 Key Players Analysis
13.1 3M
13.1.1 3M Company Information
13.1.2 3M Generic Sterile Injectable Product Portfolios and Specifications
13.1.3 3M Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 3M Main Business Overview
13.1.5 3M Latest Developments
13.2 Baxter Inc
13.2.1 Baxter Inc Company Information
13.2.2 Baxter Inc Generic Sterile Injectable Product Portfolios and Specifications
13.2.3 Baxter Inc Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Baxter Inc Main Business Overview
13.2.5 Baxter Inc Latest Developments
13.3 Fresenius Kabi
13.3.1 Fresenius Kabi Company Information
13.3.2 Fresenius Kabi Generic Sterile Injectable Product Portfolios and Specifications
13.3.3 Fresenius Kabi Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Fresenius Kabi Main Business Overview
13.3.5 Fresenius Kabi Latest Developments
13.4 Pfizer/Hospira
13.4.1 Pfizer/Hospira Company Information
13.4.2 Pfizer/Hospira Generic Sterile Injectable Product Portfolios and Specifications
13.4.3 Pfizer/Hospira Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pfizer/Hospira Main Business Overview
13.4.5 Pfizer/Hospira Latest Developments
13.5 Novartis/Sandoz
13.5.1 Novartis/Sandoz Company Information
13.5.2 Novartis/Sandoz Generic Sterile Injectable Product Portfolios and Specifications
13.5.3 Novartis/Sandoz Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Novartis/Sandoz Main Business Overview
13.5.5 Novartis/Sandoz Latest Developments
13.6 Teva
13.6.1 Teva Company Information
13.6.2 Teva Generic Sterile Injectable Product Portfolios and Specifications
13.6.3 Teva Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Teva Main Business Overview
13.6.5 Teva Latest Developments
13.7 Hikma
13.7.1 Hikma Company Information
13.7.2 Hikma Generic Sterile Injectable Product Portfolios and Specifications
13.7.3 Hikma Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Hikma Main Business Overview
13.7.5 Hikma Latest Developments
13.8 Sun Pharma
13.8.1 Sun Pharma Company Information
13.8.2 Sun Pharma Generic Sterile Injectable Product Portfolios and Specifications
13.8.3 Sun Pharma Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sun Pharma Main Business Overview
13.8.5 Sun Pharma Latest Developments
13.9 Dr. Reddy’s
13.9.1 Dr. Reddy’s Company Information
13.9.2 Dr. Reddy’s Generic Sterile Injectable Product Portfolios and Specifications
13.9.3 Dr. Reddy’s Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Dr. Reddy’s Main Business Overview
13.9.5 Dr. Reddy’s Latest Developments
13.10 Mylan
13.10.1 Mylan Company Information
13.10.2 Mylan Generic Sterile Injectable Product Portfolios and Specifications
13.10.3 Mylan Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Mylan Main Business Overview
13.10.5 Mylan Latest Developments
13.11 AstraZeneca Plc
13.11.1 AstraZeneca Plc Company Information
13.11.2 AstraZeneca Plc Generic Sterile Injectable Product Portfolios and Specifications
13.11.3 AstraZeneca Plc Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca Plc Main Business Overview
13.11.5 AstraZeneca Plc Latest Developments
13.12 Merck & Co., Inc
13.12.1 Merck & Co., Inc Company Information
13.12.2 Merck & Co., Inc Generic Sterile Injectable Product Portfolios and Specifications
13.12.3 Merck & Co., Inc Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Merck & Co., Inc Main Business Overview
13.12.5 Merck & Co., Inc Latest Developments
13.13 Hellberg Safety Ab
13.13.1 Hellberg Safety Ab Company Information
13.13.2 Hellberg Safety Ab Generic Sterile Injectable Product Portfolios and Specifications
13.13.3 Hellberg Safety Ab Generic Sterile Injectable Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Hellberg Safety Ab Main Business Overview
13.13.5 Hellberg Safety Ab Latest Developments
14 Research Findings and Conclusion